ReACT-Drug: Reaction-Template Guided Reinforcement Learning for de novo Drug Design

• URL: http://arxiv.org/abs/2512.20958v1
• Date: Wed, 24 Dec 2025 05:29:35 GMT
• Title: ReACT-Drug: Reaction-Template Guided Reinforcement Learning for de novo Drug Design
• Authors: R Yadunandan, Nimisha Ghosh,
• Abstract summary: We introduce bfReACT-Drug, a fully integrated, target-agnostic molecular design framework based on Reinforcement Learning.<n>This architecture highlights the potential of integrating structural biology, deep representation learning, and chemical rules to automate and accelerate rational drug design.
• Score: 0.34155322317700576
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: De novo drug design is a crucial component of modern drug development, yet navigating the vast chemical space to find synthetically accessible, high-affinity candidates remains a significant challenge. Reinforcement Learning (RL) enhances this process by enabling multi-objective optimization and exploration of novel chemical space - capabilities that traditional supervised learning methods lack. In this work, we introduce \textbf{ReACT-Drug}, a fully integrated, target-agnostic molecular design framework based on Reinforcement Learning. Unlike models requiring target-specific fine-tuning, ReACT-Drug utilizes a generalist approach by leveraging ESM-2 protein embeddings to identify similar proteins for a given target from a knowledge base such as Protein Data Base (PDB). Thereafter, the known drug ligands corresponding to such proteins are decomposed to initialize a fragment-based search space, biasing the agent towards biologically relevant subspaces. For each such fragment, the pipeline employs a Proximal Policy Optimization (PPO) agent guiding a ChemBERTa-encoded molecule through a dynamic action space of chemically valid, reaction-template-based transformations. This results in the generation of \textit{de novo} drug candidates with competitive binding affinities and high synthetic accessibility, while ensuring 100\% chemical validity and novelty as per MOSES benchmarking. This architecture highlights the potential of integrating structural biology, deep representation learning, and chemical synthesis rules to automate and accelerate rational drug design. The dataset and code are available at https://github.com/YadunandanRaman/ReACT-Drug/.

Related papers

• DrugR: Optimizing Molecular Drugs through LLM-based Explicit Reasoning [24.70952870676648]
  DrugR is a large language model that introduces explicit, step-by-step pharmacological reasoning into the optimization process.<n>Our approach integrates domain-specific continual pretraining, supervised fine-tuning via reverse data engineering, and self-balanced multi-granular reinforcement learning.<n> Experimental results demonstrate that DrugR achieves comprehensive enhancement across multiple properties without compromising structural similarity or target binding affinity.
  arXiv  Detail & Related papers  (2026-02-09T02:26:25Z)
• Agentic reinforcement learning empowers next-generation chemical language models for molecular design and synthesis [51.83339196548892]
  ChemCraft is a novel framework that decouples chemical reasoning from knowledge storage.<n>ChemCraft achieves superior performance with minimal inference costs.<n>This work establishes a cost-effective and privacy-preserving paradigm for AI-aided chemistry.
  arXiv  Detail & Related papers  (2026-01-25T04:23:34Z)
• Pharmacophore-Guided Generative Design of Novel Drug-Like Molecules [1.8472148461613156]
  We present a novel generative framework that balances pharmacophore similarity to reference compounds with structural diversity from active molecules.<n>We demonstrate its applicability through a case study targeting estrogen receptor modulators and antagonists for breast cancer.
  arXiv  Detail & Related papers  (2025-10-01T21:45:58Z)
• FragmentGPT: A Unified GPT Model for Fragment Growing, Linking, and Merging in Molecular Design [42.429674313921545]
  FragmentGPT generates linkers to combine disconnected molecular fragments into chemically and pharmacologically viable candidates.<n>It also learns to resolve structural redundancies-such as duplicated fragments-through intelligent merging.<n> experiments and ablation studies on real-world cancer datasets demonstrate its ability to generate chemically valid, high-quality molecules.
  arXiv  Detail & Related papers  (2025-09-14T02:17:07Z)
• DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization [53.27954325490941]
  Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives.<n>This research introduces a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model.
  arXiv  Detail & Related papers  (2025-02-11T04:00:21Z)
• BatGPT-Chem: A Foundation Large Model For Retrosynthesis Prediction [65.93303145891628]
  BatGPT-Chem is a large language model with 15 billion parameters, tailored for enhanced retrosynthesis prediction. Our model captures a broad spectrum of chemical knowledge, enabling precise prediction of reaction conditions. This development empowers chemists to adeptly address novel compounds, potentially expediting the innovation cycle in drug manufacturing and materials science.
  arXiv  Detail & Related papers  (2024-08-19T05:17:40Z)
• Contextual Molecule Representation Learning from Chemical Reaction Knowledge [24.501564702095937]
  We introduce REMO, a self-supervised learning framework that takes advantage of well-defined atom-combination rules in common chemistry. REMO pre-trains graph/Transformer encoders on 1.7 million known chemical reactions in the literature.
  arXiv  Detail & Related papers  (2024-02-21T12:58:40Z)
• Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks [0.0]
  We propose an end to end generative system, DrugGEN, for the de novo design of drug candidate molecules.<n>The system is trained using a large dataset of drug like compounds and target specific bioactive molecules.<n>It is possible to easily train models for other druggable proteins, given a dataset of experimentally known bioactive molecules.
  arXiv  Detail & Related papers  (2023-02-15T18:59:27Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning [75.95376096628135]
  We propose a novel forward synthesis framework powered by reinforcement learning (RL) for de novo drug design. In this setup, the agent learns to navigate through the immense synthetically accessible chemical space. We describe how the end-to-end training in this study represents an important paradigm in radically expanding the synthesizable chemical space.
  arXiv  Detail & Related papers  (2020-04-26T21:40:03Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.